JP2010529205A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529205A5
JP2010529205A5 JP2010512324A JP2010512324A JP2010529205A5 JP 2010529205 A5 JP2010529205 A5 JP 2010529205A5 JP 2010512324 A JP2010512324 A JP 2010512324A JP 2010512324 A JP2010512324 A JP 2010512324A JP 2010529205 A5 JP2010529205 A5 JP 2010529205A5
Authority
JP
Japan
Prior art keywords
use according
therapeutic agent
pharmaceutical composition
calcium channel
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010512324A
Other languages
English (en)
Japanese (ja)
Other versions
JP5576790B2 (ja
JP2010529205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/066576 external-priority patent/WO2008154585A1/en
Publication of JP2010529205A publication Critical patent/JP2010529205A/ja
Publication of JP2010529205A5 publication Critical patent/JP2010529205A5/ja
Application granted granted Critical
Publication of JP5576790B2 publication Critical patent/JP5576790B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010512324A 2007-06-11 2008-06-11 脳血管れん縮の予防用薬物送達システム Expired - Fee Related JP5576790B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94312407P 2007-06-11 2007-06-11
US60/943,124 2007-06-11
US97690207P 2007-10-29 2007-10-29
US60/976,902 2007-10-29
PCT/US2008/066576 WO2008154585A1 (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm

Publications (3)

Publication Number Publication Date
JP2010529205A JP2010529205A (ja) 2010-08-26
JP2010529205A5 true JP2010529205A5 (enExample) 2011-07-28
JP5576790B2 JP5576790B2 (ja) 2014-08-20

Family

ID=40096090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512324A Expired - Fee Related JP5576790B2 (ja) 2007-06-11 2008-06-11 脳血管れん縮の予防用薬物送達システム

Country Status (10)

Country Link
US (2) US8303974B2 (enExample)
EP (1) EP2164497B1 (enExample)
JP (1) JP5576790B2 (enExample)
KR (3) KR101554258B1 (enExample)
CN (3) CN105055300A (enExample)
AU (1) AU2008261668C1 (enExample)
CA (1) CA2690600C (enExample)
IL (1) IL202647A (enExample)
NZ (2) NZ581836A (enExample)
WO (1) WO2008154585A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303974B2 (en) * 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
US10092524B2 (en) * 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US9364432B2 (en) * 2007-06-11 2016-06-14 Edge Therapeutics, Inc. Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
EP2308478A1 (en) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
WO2011103591A1 (en) * 2010-02-22 2011-08-25 Edge Therapeutics Inc. Methods and compositions to treat hemorrhagic conditions of the brain
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
PL2627173T5 (pl) 2010-10-12 2019-11-29 Chiesi Farm Spa Formulacje emulsyjne klewidypiny zawierające środki przeciw mikrobom
EP2672983B1 (en) * 2011-02-11 2017-04-19 Edge Therapeutics, Inc. Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
CN102416013A (zh) * 2011-12-30 2012-04-18 湖南九典制药有限公司 西尼地平的新用途
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
WO2014165023A1 (en) 2013-03-12 2014-10-09 Carnegie Mellon University Coated vaso-occclusive device for treatment of aneurysms
CN103211812A (zh) * 2013-04-02 2013-07-24 苏州大学附属第一医院 Skf96365在治疗蛛网膜下腔出血后发生的脑血管痉挛的应用
US10403395B2 (en) * 2013-10-14 2019-09-03 SecondOpinionExpert, Inc. Method and apparatus for generating objective medical second opinion
JP2018506530A (ja) * 2015-01-30 2018-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脊柱軟膜下遺伝子送達システム
GB2556500A (en) * 2015-05-29 2018-05-30 Edge Therapeutics Inc Compositions and methods for reducing visual loss
CA2994544C (en) 2015-08-03 2021-03-30 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
BR112020000506A2 (pt) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc formulações farmacêuticas hipercomprimidas
EA202091630A1 (ru) 2018-01-12 2020-12-04 Инб Терапьютикс, Инк. Дейтерированные соединения, композиции и способы для лечения раков, связанных с активацией etbr
US20200163947A1 (en) * 2018-11-02 2020-05-28 Nortic Holdings Inc. Methods of treatment using nimodipine parenteral formulations
US11103142B2 (en) * 2019-04-02 2021-08-31 Tencent America LLC System and method for predicting vertebral artery dissection
US20200315547A1 (en) * 2019-04-02 2020-10-08 Tencent America LLC Vertebral artery dissection risk evaluation method, computer device, and storage medium
JP7716076B2 (ja) * 2021-02-04 2025-07-31 学校法人産業医科大学 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
CA2180526A1 (en) 1994-01-05 1995-07-13 Joseph C. Hogan, Jr. Method of identifying chemical compounds having selected properties for a particular application
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
JP2909418B2 (ja) * 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
WO1997033552A1 (en) 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US6123956A (en) 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6284283B1 (en) * 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) * 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
CN1480128A (zh) * 2003-08-06 2004-03-10 北京扬新科技有限公司 一种透明、隐形的外用药物制剂
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7829527B2 (en) * 2005-02-02 2010-11-09 University Of Vermont And State Agricultural College Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
US20060217340A1 (en) * 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
US8303974B2 (en) * 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm

Similar Documents

Publication Publication Date Title
JP2010529205A5 (enExample)
AU760735B2 (en) A method for treating inflammatory diseases by administering a thrombin inhibitor
TWI373335B (en) Pharmaceutical composition for therapeutic treatment of arteriosclerosi and hypertension
CN103402515B (zh) sGC刺激剂
JP6535727B2 (ja) 骨格筋疲労に対する耐性を向上させるための方法
CN101969951B (zh) 化合物在制备治疗关节炎的药物中的方法
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
TW200829244A (en) Therapeutic combinations 482
CA2806362A1 (en) Administration of rifalazil to immunocompromised patients
JP2008508279A5 (enExample)
WO2017136309A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)
CN115073421B (zh) 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺
CN101557806A (zh) 使用免疫调节化合物治疗和控制螺旋体和其它专性胞内菌疾病的方法和组合物
TWI344467B (en) Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
EP1699461A1 (en) Treatment of hepatic fibrosis with imatinib mesylate
JP2006096665A (ja) 脊柱管狭窄症治療剤
CA3015964C (en) Medicine for treating renal disease
TW201000097A (en) Medicament for the prophylaxis or treament of hypertension
EP1813282A4 (en) MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT
WO2022140169A1 (en) Preparation of tetrahydroindazole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
CA2709103A1 (en) Method and composition for treating an alpha adrenoceptor-mediated condition
AU2006263120B2 (en) Herpesvirus-derived therapeutic agent for pain
JP2016502975A5 (enExample)
TW201039824A (en) Compositions and methods for treating ocular inflammation with lower risk of increased intraocular pressure
WO2021155367A2 (en) Negative allosteric modulation of glun3-containing n-methyl-d-aspartate receptors